{"id":24231,"date":"2022-12-20T07:14:16","date_gmt":"2022-12-20T07:14:16","guid":{"rendered":"https:\/\/rhepa.se\/?p=24231"},"modified":"2022-12-20T07:14:16","modified_gmt":"2022-12-20T07:14:16","slug":"rhenman-partners-strengthens-its-investment-team-with-a-biopharma-analyst","status":"publish","type":"post","link":"https:\/\/rhepa.se\/en\/rhenman-partners-strengthens-its-investment-team-with-a-biopharma-analyst\/","title":{"rendered":"Rhenman & Partners strengthens its investment team with a biopharma analyst"},"content":{"rendered":"

Rhenman & Partners hires Amennai Beyeen as biopharma analyst. Amennai will have a particular focus on biopharma companies and the development of new drugs and treatments. He will be working closely with all colleagues of Rhenman & Partners’ five-person investment team, all based in the firm\u2019s Stockholm office. Most recently Amennai comes from Novartis, where he works with development and launches of new drugs. Amennai has previously obtained a doctorate in neuroimmunology at Karolinska Institutet in Stockholm, Sweden.<\/p>\n

“We are very happy to welcome Amennai to Rhenman & Partners. Amennai’s strong background and competence from the world of research, and his experience of pharmaceutical companies where he has been able to closely follow processes from idea to finished product make him a very good addition to our investment team,” says Henrik Rhenman, co-founder and CIO at Rhenman & Partners.<\/p>\n

“It is very exciting to start at Rhenman & Partners. I am extremely impressed by the team’s deep knowledge of the healthcare sector as well as the fund’s versatile investment process, which is reflected in its strong results over the years. I look forward to joining this competent team and contributing with my experience from the life science sector,” says Amennai Beyeen
\n\"\"<\/p>\n

Amennai will join Rhenman & Partners in April 2023.<\/p>\n","protected":false},"excerpt":{"rendered":"

Rhenman & Partners hires Amennai Beyeen as biopharma analyst. Amennai will have a particular focus on biopharma companies and the development of new drugs and treatments. He will be working closely with all colleagues of Rhenman & Partners’ five-person investment team, all based in the firm\u2019s Stockholm office. Most recently Amennai comes from Novartis, where […]<\/p>\n","protected":false},"author":9,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"om_disable_all_campaigns":false,"_mi_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"_uf_show_specific_survey":0,"_uf_disable_surveys":false},"categories":[6],"tags":[],"aioseo_notices":[],"yoast_head":"\nRhenman & Partners strengthens its investment team with a biopharma analyst - Rhenman & Partners<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/rhepa.se\/en\/rhenman-partners-strengthens-its-investment-team-with-a-biopharma-analyst\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Rhenman & Partners strengthens its investment team with a biopharma analyst - Rhenman & Partners\" \/>\n<meta property=\"og:description\" content=\"Rhenman & Partners hires Amennai Beyeen as biopharma analyst. Amennai will have a particular focus on biopharma companies and the development of new drugs and treatments. He will be working closely with all colleagues of Rhenman & Partners’ five-person investment team, all based in the firm\u2019s Stockholm office. Most recently Amennai comes from Novartis, where […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/rhepa.se\/en\/rhenman-partners-strengthens-its-investment-team-with-a-biopharma-analyst\/\" \/>\n<meta property=\"og:site_name\" content=\"Rhenman & Partners\" \/>\n<meta property=\"article:published_time\" content=\"2022-12-20T07:14:16+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/rhepa.se\/wp-content\/uploads\/2022\/12\/Ame_landscape-1-300x225.jpg\" \/>\n<meta name=\"author\" content=\"Karin Hjert\u00e9n\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Karin Hjert\u00e9n\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/rhepa.se\/en\/rhenman-partners-strengthens-its-investment-team-with-a-biopharma-analyst\/\",\"url\":\"https:\/\/rhepa.se\/en\/rhenman-partners-strengthens-its-investment-team-with-a-biopharma-analyst\/\",\"name\":\"Rhenman & Partners strengthens its investment team with a biopharma analyst - Rhenman & Partners\",\"isPartOf\":{\"@id\":\"https:\/\/rhepa.se\/en\/#website\"},\"datePublished\":\"2022-12-20T07:14:16+00:00\",\"dateModified\":\"2022-12-20T07:14:16+00:00\",\"author\":{\"@id\":\"https:\/\/rhepa.se\/en\/#\/schema\/person\/a6c15c256c7b7ae64d16c43f8f1268cb\"},\"breadcrumb\":{\"@id\":\"https:\/\/rhepa.se\/en\/rhenman-partners-strengthens-its-investment-team-with-a-biopharma-analyst\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/rhepa.se\/en\/rhenman-partners-strengthens-its-investment-team-with-a-biopharma-analyst\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/rhepa.se\/en\/rhenman-partners-strengthens-its-investment-team-with-a-biopharma-analyst\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/rhepa.se\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Rhenman & Partners strengthens its investment team with a biopharma analyst\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/rhepa.se\/en\/#website\",\"url\":\"https:\/\/rhepa.se\/en\/\",\"name\":\"Rhenman & Partners\",\"description\":\"Asset Management AB\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/rhepa.se\/en\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/rhepa.se\/en\/#\/schema\/person\/a6c15c256c7b7ae64d16c43f8f1268cb\",\"name\":\"Karin Hjert\u00e9n\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/rhepa.se\/en\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/9a16a8a0b2c63b68ae9f95a33aaedbfd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/9a16a8a0b2c63b68ae9f95a33aaedbfd?s=96&d=mm&r=g\",\"caption\":\"Karin Hjert\u00e9n\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Rhenman & Partners strengthens its investment team with a biopharma analyst - Rhenman & Partners","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/rhepa.se\/en\/rhenman-partners-strengthens-its-investment-team-with-a-biopharma-analyst\/","og_locale":"en_US","og_type":"article","og_title":"Rhenman & Partners strengthens its investment team with a biopharma analyst - Rhenman & Partners","og_description":"Rhenman & Partners hires Amennai Beyeen as biopharma analyst. Amennai will have a particular focus on biopharma companies and the development of new drugs and treatments. He will be working closely with all colleagues of Rhenman & Partners’ five-person investment team, all based in the firm\u2019s Stockholm office. Most recently Amennai comes from Novartis, where […]","og_url":"https:\/\/rhepa.se\/en\/rhenman-partners-strengthens-its-investment-team-with-a-biopharma-analyst\/","og_site_name":"Rhenman & Partners","article_published_time":"2022-12-20T07:14:16+00:00","og_image":[{"url":"https:\/\/rhepa.se\/wp-content\/uploads\/2022\/12\/Ame_landscape-1-300x225.jpg"}],"author":"Karin Hjert\u00e9n","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Karin Hjert\u00e9n","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/rhepa.se\/en\/rhenman-partners-strengthens-its-investment-team-with-a-biopharma-analyst\/","url":"https:\/\/rhepa.se\/en\/rhenman-partners-strengthens-its-investment-team-with-a-biopharma-analyst\/","name":"Rhenman & Partners strengthens its investment team with a biopharma analyst - Rhenman & Partners","isPartOf":{"@id":"https:\/\/rhepa.se\/en\/#website"},"datePublished":"2022-12-20T07:14:16+00:00","dateModified":"2022-12-20T07:14:16+00:00","author":{"@id":"https:\/\/rhepa.se\/en\/#\/schema\/person\/a6c15c256c7b7ae64d16c43f8f1268cb"},"breadcrumb":{"@id":"https:\/\/rhepa.se\/en\/rhenman-partners-strengthens-its-investment-team-with-a-biopharma-analyst\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/rhepa.se\/en\/rhenman-partners-strengthens-its-investment-team-with-a-biopharma-analyst\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/rhepa.se\/en\/rhenman-partners-strengthens-its-investment-team-with-a-biopharma-analyst\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/rhepa.se\/en\/"},{"@type":"ListItem","position":2,"name":"Rhenman & Partners strengthens its investment team with a biopharma analyst"}]},{"@type":"WebSite","@id":"https:\/\/rhepa.se\/en\/#website","url":"https:\/\/rhepa.se\/en\/","name":"Rhenman & Partners","description":"Asset Management AB","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/rhepa.se\/en\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/rhepa.se\/en\/#\/schema\/person\/a6c15c256c7b7ae64d16c43f8f1268cb","name":"Karin Hjert\u00e9n","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/rhepa.se\/en\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/9a16a8a0b2c63b68ae9f95a33aaedbfd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/9a16a8a0b2c63b68ae9f95a33aaedbfd?s=96&d=mm&r=g","caption":"Karin Hjert\u00e9n"}}]}},"_links":{"self":[{"href":"https:\/\/rhepa.se\/en\/wp-json\/wp\/v2\/posts\/24231"}],"collection":[{"href":"https:\/\/rhepa.se\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/rhepa.se\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/rhepa.se\/en\/wp-json\/wp\/v2\/users\/9"}],"replies":[{"embeddable":true,"href":"https:\/\/rhepa.se\/en\/wp-json\/wp\/v2\/comments?post=24231"}],"version-history":[{"count":1,"href":"https:\/\/rhepa.se\/en\/wp-json\/wp\/v2\/posts\/24231\/revisions"}],"predecessor-version":[{"id":24234,"href":"https:\/\/rhepa.se\/en\/wp-json\/wp\/v2\/posts\/24231\/revisions\/24234"}],"wp:attachment":[{"href":"https:\/\/rhepa.se\/en\/wp-json\/wp\/v2\/media?parent=24231"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/rhepa.se\/en\/wp-json\/wp\/v2\/categories?post=24231"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/rhepa.se\/en\/wp-json\/wp\/v2\/tags?post=24231"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}